Q (sonnet-5.5): What percentage of endometrial cancer samples have hypermutation (>5000 mutations) and how does this correlate with histological subtype? ▶ read_guide { "uri": "cbioportal://clinical-data-guide" } ▶ list_studies { "search": "endometrial" } ▶ search_oncotree { "search_term": "endometrial" } ◀ result # Clinical Data Query Guide ## Overview Clinical data in cBioPortal is stored at both patient and sample levels. Understanding the distinction is crucial for accurate analysis. ## Data Organization ### Patient-Level vs Sample-Level Data - **Patient-level**: Demographics, overall survival, disease stage (stored once per patient) - **Sample-level**: Sample type, sequencing platform, purity (can have multiple per patient) ### Key Tables - `clinical_patient`: Patient-level clinical attributes - `clinical_sample`: Sample-level clinical attributes - `clinical_data_derived`: Pre-joined view combining both levels - `clinical_attribute_meta`: Metadata about available clinical attributes ## Recommended Approach: Use clinical_data_derived The `clinical_data_derived` table is pre-joined and optimized for most queries: ```sql -- Get clinical data for specific attributes SELECT sample_unique_id, patient_unique_id, attribute_name, attribute_value FROM clinical_data_derived WHERE cancer_study_identifier = 'your_study_id' AND attribute_name IN ('CANCER_TYPE', 'SAMPLE_TYPE', 'TMB_NONSYNONYMOUS'); ``` ## Clinical Attribute Discovery ### Use clinical_attribute_meta for Discovering Available Attributes **Always start here** to see what clinical attributes are available for a specific study: ```sql -- Discover available clinical attributes for a study SELECT attr_id, description, patient_attribute, cancer_study_id FROM clinical_attribute_meta WHERE cancer_study_id = ( SELECT cancer_study_id FROM cancer_study WHERE cancer_study_identifier = 'your_study_id' ) ORDER BY patient_attribute, attr_id; ``` **Key Fields:** - **attr_id**: matches attr_id in clinical_sample/clinical_patient tables - **description**: human-readable description of the attribute - **patient_attribute**: true = patient attribute, false = sample attribute - **cancer_study_id**: links to cancer_study table (filter by study) ## Attribute Semantics and Matching ### Case-Insensitive Matching for Attribute Values Clinical values are free text across studies and may differ only by case. For example, a controlled-looking value such as germline mutation status may appear as `GERMLINE`, `Germline`, or another case variant. When filtering `clinical_data_derived.attribute_value`, use case-insensitive matching unless you have already profiled the exact values in the target study: ```sql -- Correct: case-insensitive clinical value filter SELECT DISTINCT sample_unique_id, patient_unique_id FROM clinical_data_derived WHERE cancer_study_identifier = 'your_study_id' AND attribute_name = 'MUTATION_STATUS' AND upper(attribute_value) = 'GERMLINE'; ``` Do not write `attribute_value = 'GERMLINE'` without first checking all distinct values for that attribute in the study. ### Query the Requested Attribute, Not a Proxy Do not infer one clinical attribute from a related subtype or marker. Query the actual requested attribute when it … (17073 more chars) ◀ result {"result":[{"cancer_study_identifier":"ucec_ancestry_cds_msk_2023","name":"Endometrial Cancer (MSK, Cancer Discovery 2023)","type_of_cancer_id":"ucec","sample_count":1882,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_ancestry_cds_msk_2023"},{"cancer_study_identifier":"ucec_tcga","name":"Uterine Corpus Endometrial Carcinoma (TCGA, Firehose Legacy)","type_of_cancer_id":"ucec","sample_count":549,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_tcga"},{"cancer_study_identifier":"ucec_tcga_gdc","name":"Endometrial Carcinoma (TCGA GDC, 2025)","type_of_cancer_id":"ucec","sample_count":547,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_tcga_gdc"},{"cancer_study_identifier":"ucec_tcga_pan_can_atlas_2018","name":"Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas)","type_of_cancer_id":"ucec","sample_count":529,"has_guide":true,"url":"https://www.cbioportal.org/study/summary?id=ucec_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"ucec_tcga_pub","name":"Uterine Corpus Endometrial Carcinoma (TCGA, Nature 2013)","type_of_cancer_id":"ucec","sample_count":373,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_tcga_pub"},{"cancer_study_identifier":"ucec_msk_2018","name":"Endometrial Cancer (MSK, 2018)","type_of_cancer_id":"ucec","sample_count":197,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_msk_2018"},{"cancer_study_identifier":"ucec_ccr_msk_2022","name":"Endometrial Carcinoma MSI (MSK, Clin Cancer Res 2022)","type_of_cancer_id":"ucec","sample_count":181,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_ccr_msk_2022"},{"cancer_study_identifier":"ucec_cptac_2020","name":"Endometrial Carcinoma (CPTAC, Cell 2020)","type_of_cancer_id":"ucec","sample_count":81,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_cptac_2020"},{"cancer_study_identifier":"ucs_msk_2024","name":"Endometrial Carcinoma (MSK, Molecular Oncology 2024)","type_of_cancer_id":"ucec","sample_count":69,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucs_msk_2024"},{"cancer_study_identifier":"ucec_ccr_cfdna_msk_2022","name":"Endometrial Carcinoma cfDNA (MSK, Clin Cancer Res 2022)","type_of_cancer_id":"ucec","sample_count":44,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_ccr_cfdna_msk_2022"},{"cancer_study_identifier":"ucec_msk_2024","name":"Endometrial and Ovarian Cancer (MSK, Nature Medicine 2024)","type_of_cancer_id":"mixed","sample_count":33,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ucec_msk_2024"},{"cancer_study_identifier":"uec_msk_2024","name":"Endometrial cancer HR-positive (MSK, 2024)","type_of_cancer_id":"ucec","sample_count":24,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=uec_msk_2024"},{"cancer_study_identifier":"uccc_nih_2017","name":"Uterine Clear Cell Carcinoma (NIH, Cancer 2017)","type_of_cancer_id … (447 more chars) ◀ result {"result":[{"code":"ESS","name":"Endometrial Stromal Sarcoma","score":60,"mainType":"Uterine Sarcoma","tissue":"Uterus","hierarchy":"UTERUS > USARC > ESS"},{"code":"UCEC","name":"Endometrial Carcinoma","score":60,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC"},{"code":"HGESS","name":"High-Grade Endometrial Stromal Sarcoma","score":50,"mainType":"Uterine Sarcoma","tissue":"Uterus","hierarchy":"UTERUS > USARC > ESS > HGESS"},{"code":"LGESS","name":"Low-Grade Endometrial Stromal Sarcoma","score":50,"mainType":"Uterine Sarcoma","tissue":"Uterus","hierarchy":"UTERUS > USARC > ESS > LGESS"},{"code":"UMEC","name":"Uterine Mixed Endometrial Carcinoma","score":50,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UMEC"},{"code":"OUTT","name":"Other Uterine Tumor","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > OUTT"},{"code":"UASC","name":"Uterine Adenosquamous Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UASC"},{"code":"UCCC","name":"Uterine Clear Cell Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UCCC"},{"code":"UCS","name":"Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UCS"},{"code":"UDDC","name":"Uterine Dedifferentiated Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UDDC"},{"code":"UEC","name":"Uterine Endometrioid Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UEC"},{"code":"UMC","name":"Uterine Mucinous Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UMC"},{"code":"UMNC","name":"Uterine Mesonephric Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UMNC"},{"code":"UNEC","name":"Uterine Neuroendocrine Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UNEC"},{"code":"UPDC","name":"Poorly Differentiated Carcinoma of the Uterus","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UPDC"},{"code":"USC","name":"Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > USC"},{"code":"UUC","name":"Uterine Undifferentiated Carcinoma","score":45,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UUC"}]} ▶ get_study_guide { "study_id": "ucec_tcga_pan_can_atlas_2018" } ◀ result # Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas) **Study ID:** `ucec_tcga_pan_can_atlas_2018` See `_tcga_pancan_template.md` for common TCGA clinical attributes. ## Study-Specific Attributes ### Molecular Classification (TCGA) | Attribute | Description | Values (patients) | |-----------|-------------|--------| | `SUBTYPE` | TCGA molecular subtype | `UCEC_CN_HIGH` 163, `UCEC_MSI` 148, `UCEC_CN_LOW` 147, `UCEC_POLE` 49, blank 22 | ### Histology There is no `HISTOLOGICAL_TYPE` attribute; use `CANCER_TYPE_DETAILED`, plus `GRADE` for grade. | Attribute | Values (samples) | |-----------|--------| | `CANCER_TYPE_DETAILED` | Uterine Endometrioid Carcinoma 399, Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma 109, Uterine Mixed Endometrial Carcinoma 21 | | `GRADE` | G3 302, G2 119, G1 97, High Grade 11 | `AJCC_PATHOLOGIC_TUMOR_STAGE` is blank for all samples. ## Molecular Subtypes | Subtype | Characteristics | Prognosis | |---------|-----------------|-----------| | **POLE** | Ultra-hypermutated (>100 mut/Mb), POLE exonuclease mutations | Excellent | | **MSI** | Hypermutated, microsatellite instability, MLH1 silencing | Intermediate | | **CN-low** | Microsatellite stable, few copy number alterations | Intermediate | | **CN-high** | Serous-like, TP53 mutations, extensive CNA | Poor | ## Key Genes | Gene | Frequency | Subtype Association | |------|-----------|---------------------| | PTEN | ~65% | CN-low, MSI | | PIK3CA | ~50% | All subtypes | | PIK3R1 | ~30% | CN-low | | ARID1A | ~35% | MSI | | TP53 | ~25% | CN-high (>90% in this subtype) | | KRAS | ~20% | Various | | CTNNB1 | ~20% | CN-low | | POLE | ~7% | Defines POLE subtype | ## Notes - TCGA molecular classification has prognostic value and guides treatment - POLE and MSI subtypes are hypermutated but have different mechanisms - TP53 mutations with CN-high pattern indicate serous-like behavior regardless of histology - POLE mutations should be in exonuclease domain (proofreading) to be driver - MSI-H tumors respond well to immunotherapy ▶ clickhouse_run_select_query { "query": "WITH mc AS ( SELECT sample_unique_id, toFloat64OrNull(attribute_value) AS m FROM clinical_data_derived WHERE cancer_study_identifier='ucec_tcga_pan_can_atlas_2018' AND attribute_name='MUTATION_COUNT'), h AS ( SELECT sample_unique_id, anyIf(attribute_value, attribute_name='CANCER_TYPE_DETAILED') AS hist, anyIf(attribute_value, attribute_name='SUBTYPE') AS sub FROM clinical_data_derived WHERE cancer_study_identifier='ucec_tcga_pan_can_atlas_2018' AND attribute_name IN ('CANCER_TYPE_DETAILED','SUBTYPE') GROUP BY sample_unique_id) SELECT h.hist AS histology, count() AS n, countIf(m IS NOT NULL) AS with_count, countIf(m>5000) AS hyper, round(100*hyper/with_count,1) AS pct, max(m) AS maxm, quantile(0.5)(m) AS med FROM mc JOIN h USING sample_unique_id GROUP BY histology WITH TOTALS ORDER BY n DESC" } ◀ result {"rows":[{"histology":"Uterine Endometrioid Carcinoma","n":399,"with_count":388,"hyper":34,"pct":8.8,"maxm":13853,"med":142.5},{"histology":"Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma","n":109,"with_count":108,"hyper":2,"pct":1.9,"maxm":25697,"med":54},{"histology":"Uterine Mixed Endometrial Carcinoma","n":21,"with_count":21,"hyper":2,"pct":9.5,"maxm":10492,"med":61}]} ▶ clickhouse_run_select_query { "query": "WITH mc AS ( SELECT sample_unique_id, toFloat64OrNull(attribute_value) AS m FROM clinical_data_derived WHERE cancer_study_identifier='ucec_tcga_pan_can_atlas_2018' AND attribute_name='MUTATION_COUNT') SELECT m>5000 AS hyper, count() n, min(m) mn, max(m) mx FROM mc GROUP BY hyper UNION ALL SELECT 2, count(), quantile(0.9)(m), quantile(0.75)(m) FROM mc" } ◀ result {"rows":[{"n":12},{"hyper":0,"n":479,"mn":0,"mx":4826},{"hyper":1,"n":38,"mn":5113,"mx":25697},{"hyper":2,"n":529,"mn":1806.4000000000055,"mx":559}]} ▶ clickhouse_run_select_query { "query": "WITH mc AS ( SELECT sample_unique_id, toFloat64OrNull(attribute_value) AS m FROM clinical_data_derived WHERE cancer_study_identifier='ucec_tcga_pan_can_atlas_2018' AND attribute_name='MUTATION_COUNT'), h AS ( SELECT sample_unique_id, anyIf(attribute_value, attribute_name='SUBTYPE') AS sub FROM clinical_data_derived WHERE cancer_study_identifier='ucec_tcga_pan_can_atlas_2018' AND attribute_name='SUBTYPE' GROUP BY sample_unique_id) SELECT h.sub AS subtype, countIf(m IS NOT NULL) AS n, countIf(m>5000) AS hyper FROM mc JOIN h USING sample_unique_id GROUP BY subtype ORDER BY n DESC" } ▶ resolve_and_route { "studyIds": [ "ucec_tcga_pan_can_atlas_2018" ] } ◀ result {"rows":[]} ◀ result {"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"ucec_tcga_pan_can_atlas_2018","name":"Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas)","sampleCount":529,"studyViewUrl":"https://www.cbioportal.org/study?id=ucec_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["ucec_tcga_pan_can_atlas_2018_gistic","ucec_tcga_pan_can_atlas_2018_log2CNA","ucec_tcga_pan_can_atlas_2018_mutations","ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","ucec_tcga_pan_can_atlas_2018_rppa","ucec_tcga_pan_can_atlas_2018_rppa_Zscores","ucec_tcga_pan_can_atlas_2018_structural_variants"],"genericAssayProfiles":["ucec_tcga_pan_can_atlas_2018_armlevel_cna","ucec_tcga_pan_can_atlas_2018_genetic_ancestry","ucec_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","ucec_tcga_pan_can_atlas_2018_methylation_hm450"],"heatmapProfileIds":["ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","ucec_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","ucec_tcga_pan_can_atlas_2018_rppa_Zscores"],"availableComparisonTabs":["overlap","clinical","survival","alterations","mutations","mrna","protein","generic_assay_armlevel_cna","generic_assay_genetic_ancestry","generic_assay_methylation"]}}]}} ▶ navigate_to_group_comparison { "studyIds": [ "ucec_tcga_pan_can_atlas_2018" ], "groups": [ { "name": "Endometrioid", "studyViewFilter": { "clinicalDataFilters": [ { "attributeId": "CANCER_TYPE_DETAILED", "values": [ { "value": "Uterine Endometrioid Carcinoma" } ] } ] } }, { "name": "Serous", "studyViewFilter": { "clinicalDataFilters": [ { "attributeId": "CANCER_TYPE_DETAILED", "values": [ { "value": "Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma" } ] } ] } }, { "name": "Mixed", "studyViewFilter": { "clinicalDataFilters": [ { "attributeId": "CANCER_TYPE_DETAILED", "values": [ { "value": "Uterine Mixed Endometrial Carcinoma" } ] } ] } } ], "tab": "clinical" } ◀ result {"success":true,"message":"Navigating to https://www.cbioportal.org/comparison/clinical?comparisonId=6abb41ccc2115c492d8855c4","url":"https://www.cbioportal.org/comparison/clinical?comparisonId=6abb41ccc2115c492d8855c4","data":{"description":"Group comparison (3 custom groups)","studies":["ucec_tcga_pan_can_atlas_2018"],"totalGroups":3,"groups":[{"name":"Endometrioid","sampleCount":399},{"name":"Serous","sampleCount":109},{"name":"Mixed","sampleCount":21}],"studyViewUrl":"https://www.cbioportal.org/study?id=ucec_tcga_pan_can_atlas_2018","groupUrls":[{"groupName":"Endometrioid","url":"https://www.cbioportal.org/study?id=ucec_tcga_pan_can_atlas_2018#filterJson=%7B%22clinicalDataFilters%22%3A%5B%7B%22attributeId%22%3A%22CANCER_TYPE_DETAILED%22%2C%22values%22%3A%5B%7B%22value%22%3A%22Uterine%20Endometrioid%20Carcinoma%22%7D%5D%7D%5D%7D"},{"groupName":"Serous","url":"https://www.cbioportal.org/study?id=ucec_tcga_pan_can_atlas_2018#filterJson=%7B%22clinicalDataFilters%22%3A%5B%7B%22attributeId%22%3A%22CANCER_TYPE_DETAILED%22%2C%22values%22%3A%5B%7B%22value%22%3A%22Uterine%20Serous%20Carcinoma%2FUterine%20Papillary%20Serous%20Carcinoma%22%7D%5D%7D%5D%7D"},{"groupName":"Mixed","url":"https://www.cbioportal.org/study?id=ucec_tcga_pan_can_atlas_2018#filterJson=%7B%22clinicalDataFilters%22%3A%5B%7B%22attributeId%22%3A%22CANCER_TYPE_DETAILED%22%2C%22values%22%3A%5B%7B%22value%22%3A%22Uterine%20Mixed%20Endometrial%20Carcinoma%22%7D%5D%7D%5D%7D"}],"pageDescription":"Clinical attribute distributions compared across Endometrioid (399) vs Serous (109) vs Mixed (21)."}} ═ answer (success) In the TCGA PanCancer Atlas endometrial cohort, 38 of 517 samples (7.4%) have more than 5,000 mutations. I used this cohort because only exome-scale data can reach that mutation count. The database has about 14 other endometrial studies, mostly targeted panels, so tell me if you want a different one. Cohort: [Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas)](https://www.cbioportal.org/study/summary?id=ucec_tcga_pan_can_atlas_2018). The unit is samples, using the total mutation count per sample. 12 of the 529 samples have no mutation count and are excluded. **Hypermutation (>5,000 mutations) by histology** | Histology | Samples with a count | Above 5,000 | % | Median mutation count | |---|---|---|---|---| | Endometrioid | 388 | 34 | 8.8% | 142.5 | | Serous / papillary serous | 108 | 2 | 1.9% | 54 | | Mixed endometrial | 21 | 2 | 9.5% | 61 | | **All** | **517** | **38** | **7.4%** | | - **Endometrioid:** these tumors account for 34 of the 38 hypermutated samples (89%). - **Serous:** hypermutation is rare, at 2 of 108 samples. - **Mixed:** the 9.5% rests on only 2 of 21 samples, so it is too small to compare reliably. - **Cutoff:** the 5,000 threshold splits the cohort cleanly. No sample falls between 4,826 and 5,113 mutations, and the 38 hypermutated samples range from 5,113 to 25,697. - **Serous outliers:** the serous group includes the cohort's highest count (25,697), so those 2 hypermutated serous samples are extreme. - **Statistics:** I have not computed a p-value or any other statistical test. These are descriptive counts. I could not break these counts down by TCGA molecular subtype (POLE, MSI, CN-low, CN-high) because that join returned no rows. The study notes describe POLE and MSI tumors as the hypermutated classes, but that is background, not something I confirmed in this data. Links: - [Compare the three histology groups](https://www.cbioportal.org/comparison/clinical?comparisonId=6abb41ccc2115c492d8855c4) (Endometrioid 399, Serous 109, Mixed 21 samples). Its clinical tab includes mutation count and TMB. - [Study overview](https://www.cbioportal.org/study?id=ucec_tcga_pan_can_atlas_2018)